Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab

Fig. 2

Efficacy of the combination Regorafenib-Avelumab in cold soft-tissue sarcoma patients. a Waterfall plot and b Spider plot of the maximum change in tumor size in patients with sarcoma treated with regorafenib plus avelumab and eligible for efficacy (n = 43). Kaplan–Meier curves of the progression-free survival (c) and overall survival (d). RECIST Response Evaluation Criteria in Solid Tumors

Back to article page